Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: Perfused vs. ischemic and early vs. late treatment

Current Eye Research

Volumn 36, Issue 12, 2011, Pages 1164-1170

  Decroos, Francis Char ^a   Ehlers, Justis P ^a   Stinnett, Sandra ^a   Fekrat, Sharon ^a  

^a DUKE UNIVERSITY EYE CENTER   (United States)

Author keywords

Avastin; Bevacizumab; Central retinal vein occlusion (CRVO)

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; TRIAMCINOLONE ACETONIDE;

AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PERFUSION; PRIORITY JOURNAL; RETINA FOVEA; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; THICKNESS; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 81255195358     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.607537     Document Type: Article

References (31)

1. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The blue mountains eye study. Arch Ophthalmol 1996;114:1243-1247.
2. Group TCVOS. Natural history and clinical management of central retinal vein occlusion. The Central Vein occlusion study group. Arch Ophthalmol 1997;115:486-491.
3. Brown DM, Campochiaro PA, Singh RP et al. CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117: 1124-1133.
4. Ip MS, Scott IU, VanVeldhuisen PC et al.; SCORE study research group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-1114.
5. Peer J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998;105:412-416.
6. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
7. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002;133:373-385.
8. Noma H, Funatsu H, Yamasaki M et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005;140:256-261.
9. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990;50:1774-1778.
10. Funk M, Kriechbaum K, Prager F et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025-1032.
11. Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007;144:864-871.
12. Hoeh AE, Ach T, Schaal KB, Scheuerle AF, Dithmar S. Longterm follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009;247:1635-1641.
13. Rensch F, Jonas JB, Spandau UH. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion. Acta Ophthalmol 2009;87:77-81.
14. Priglinger SG, Wolf AH, Kreutzer TC et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: Six-month results of a prospective trial. Retina (Philadelphia, Pa) 2007;27:1004-1012.
15. Algvere PV, Von Wendt G, Gudmundsson J, Seregard S, Kvanta A. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®)). Acta Ophthalmol 2010;88:836-841.
16. Figueroa MS, Contreras I, Noval S, Arruabarrena C. Results of bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol 2010;94:1052-1056.
17. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology 1983;90:458-474.
18. Larsson J, Bauer B, Andreasson S. The 30-Hz flicker cone ERG for monitoring the early course of central retinal vein occlusion. Acta Ophthalmol Scand 2000;78:187-190.
19. Ota M, Tsujikawa A, Murakami T et al. Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. Br J Ophthalmol 2007;91:1644-1649.
20. CVOS. Baseline and early natural history report. The central vein occlusion study. Arch Ophthalmol 1993;111:1087-1095.
21. Iturralde D, Spaide RF, Meyerle CB et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina (Philadelphia, Pa) 2006;26:279-284.
22. Beutel J, Ziemssen F, Luke M, Partsch M, Bartz-Schmidt KU, Gelisken F; Bevacizumab Study Group. Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: One-year results. Int Ophthalmol 2010;30:15-22.
23. Kriechbaum K, Michels S, Prager F et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: A prospective study. Br J Ophthalmol 2008;92:518-522.
24. Pai SA, Shetty R, Vijayan PB et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007;143:601-606.
25. Prager F, Michels S, Kriechbaum K et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452-456.
26. Stahl A, Struebin I, Hansen LL, Agostini HT, Feltgen N. Bevacizumab in central retinal vein occlusion: A retrospective analysis after 2 years of treatment. Eur J Ophthalmol 2010;20:180-185.
27. Pieramici DJ, Rabena M, Castellarin AA et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008;115:e47-e54.
28. Spaide RF, Chang LK, Klancnik JM et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.
29. Rouvas A, Petrou P, Vergados I et al. Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: A prospective study. Graefes Arch Clin Exp Ophthalmol 2009;247:1609-1616.
30. Campochiaro PA, Hafiz G, Channa R et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: Two-year outcomes. Ophthalmology 2010;117:2387-2394.e1.
31. Singh RP. Long-term outcomes using ranibizumab for treatment of central retinal vein occlusion. American Academy of Ophthalmology: Retina Suspecialty Day. 2010.